Overview
This work aims to evaluate the effects of the association of green propolis extract with royal jelly on inflammation and oxidative stress in participants with chronic kidney diseases (CKD) and Systemic arterial hypertension (SAH), in a longitudinal, randomized, double-blind, placebo-controlled clinical trial that will be carried out for 2 months.
Description
Propolis and royal jelly are bee products. Propolis is a resinous mixture produced by bees with their saliva and the addition of wax, from exudates collected from buds and plant sap. Royal jelly is a substance produced in the hypopharyngeal glands of young worker bees. Both products are rich in bioactive compounds such as polyphenols. The combination of propolis extract and royal jelly, substances constituted by the combination of several chemical components with potential biological activity, may emerge as a promising adjuvant therapeutic alternative for patients with CKD and SAH.
Eligibility
Inclusion Criteria:
- patients in stages 3 and 5 of CKD (GFR from 15 to 59 mL/min),
- patients receiving ambulatorial nutrition treatment at least 6 months
- patients on regular Hemodialysis treatment for at least 6 months
- patients using one to three antihypertensive drugs
Exclusion Criteria:
- autoimmune and infectious diseases,
- diabetes
- cancer
- AIDS
- pregnant women
- patients using catabolic drugs or antibiotics;
- patients with catheter access to hemodialysis;
- patients using antioxidant vitamin supplements, prebiotics, probiotics, symbiotic,
- Patients on regular intake of propolis who are allergic to corn starch or report being allergic to bee stings.
- patients with acute myocardial infarction (AMI) and/or cerebrovascular accident (CVA)